Avicenna.AI partners with CARPL.ai on AI to detect life-threatening conditions

Avicenna.AI’s advanced AI detection tools are now available via the CARPL platform.

Marseille, FRANCE – November 22, 2022 – Medical imaging AI specialist Avicenna.AI today
announced a distribution agreement with CARPL.ai, a technology platform that enables service provider-oriented testing, validation and deployment of AI applications to healthcare providers.

As the number of AI applications coming into the clinical realm increases, it can be challenging for healthcare providers to access, assess and then integrate these solutions into their clinical workflows. CARPL bridges this gap by acting as an intermediary platform for the development, testing, distribution and deployment of AI applications.

The CARPL platform now includes Avicenna.AI’s range of CINA solutions for neurovascular and thoraco-abdominal pathologies, which use deep learning to identify, detect and quantify life-threatening pathologies from CT medical images. The FDA-cleared and CE-Marked tools are seamlessly integrated within the clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.
Using a combination of deep learning and machine learning technologies, the CINA solutions
automatically detect and prioritize cases within seconds, and assess them for severity, seamlessly alerting radiologists within their existing systems and workflow.

“CARPL.ai specializes in driving the adoption of radiology AI solutions into clinical workflows and improves patient outcomes, by enabling and empowering healthcare service providers to discover, explore, and validate cutting-edge AI and then deploy it in their environment with confidence,” said Dr. Vidur Mahajan, Chief Executive Officer of CARPL.ai. “When it comes to stroke care and other life-threatening conditions, we are delighted to now be able to offer Avicenna’s portfolio as a comprehensive solution to our customers.”

“We’re excited to partner with a leading platform like CARPL, which has a strong presence in key new markets for us, including Australia, Brazil and India,” said Cyril Di Grandi, co-founder, and CEO of Avicenna.AI. “They are also deployed in many large hospital environments, which is exactly what our solutions are designed for – delivering faster detection of critical conditions, improving radiology efficiency and supporting better patient outcomes.”

Avicenna.AI will be attending RSNA 2022, November 27 – 30. To book a meeting, email
contact@avicenna.Ai.

About Avicenna.AI 

Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and support emergency room triage. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning. 

www.avicenna.ai

About CARPL.ai

CARPL is an end-to-end technology platform for the development, testing, distribution and
deployment of medical imaging AI applications in clinical workflows. Used by some of the world’s top AI researchers and health systems, it connects AI applications and healthcare providers helping improve access, affordability, and quality of medical care. 

www.carpl.ai

Avicenna.AI partners with deepc to revolutionize Stroke Patient Care

Logo deepc

Marseille, FRANCE – September, 27, 2022. Medical imaging specialist Avicenna.AI today announced a groundbreaking partnership with the MedTech company deepc, offering one of the leading radiology AI platforms (deepcOS), to give healthcare providers access to their stroke suite.

This move facilitates a step change in patient management for stroke, enabling rapid treatment decisions by combining a uniquely comprehensive stroke management technology with a platform that seamlessly integrates into radiologist’s clinical workflow.

Every Second Counts.

Avicenna.AI’s stroke suite gives radiologists exactly the tools they need to rapidly and automatically identify, triage, and assess patients, enabling faster decision-making and saving lives.

Avicenna.AI’s CINA stroke suite provides a full range of tools powered by deep learning to automatically identify acute abnormalities and support the emergency imaging department. It comprises two FDA-cleared, CE-marked tools for automatic triage, and one CE-marked quantification tool:

  • CINA-LVO is a triage tool that instantly flags suspected Large Vessel Occlusion (LVO) on CT angiography. Given that every minute of untreated LVO means two million neurons are lost, early diagnosis is critical.
  • Real-time trial tool CINA-ICH highlights suspected acute Intracranial Hemorrhage (ICH) on CT scans, efficiently prioritizing cases, drastically reducing the time to treatment. ICH affects over two million people worldwide with a 40-50% mortality rate within one month, so accurate early
    detection and treatment are vital.
  • CINA-ASPECTS is a quantification tool that automatically measures an ASPECT Score to assess ischemic changes in stroke. CINA-ASPECTS enables faster, more consistent, and more precise interpretations for assessing acute ischemic stroke.

To reach its potential, this technology needs to be available to those who need it. That’s where deepc comes in, by creating a cutting-edge AI ecosystem providing radiologists instant access to AI-powered technologies. The platform is changing the way AI is adopted by integrating directly into the clinical workflow. Avicenna.AI’s full stroke suite is now available through the platform, meaning more physicians and patients can benefit from its tools than ever before.

John Moulden, Chief Commercial Officer at deepc: “Our companies bring a challenger mindset to this amazing partnership, and together we offer truly revolutionary technology to healthcare providers and their radiology departments. Looking forward to working together with Avicenna.AI!“

Olivier Fuseri, Sales Manager at Avicenna.AI: “We are thrilled that our solutions for Stroke are integrated in such a groundbreaking platform as deepcOS. Together we are committed to transform the future of radiology through our combined technologies.”

Stroke Detection AI Tool Approved for Medicare NTAP

Triage tool for CT Scan

Paris, FRANCE – November 24th, 2020 – Medical imaging AI specialist Avicenna.AI today announced that its CINA Head software qualifies for the new technology add-on payment (NTAP) recently approved by the Centers for Medicare & Medicaid Services (CMS).

The NTAP is available for radiological computer-assisted triage and notification software systems like CINA Head, which analyzes computed tomography angiogram (CTA) images and urgently notifies clinical team members when a suspected large vessel occlusion (LVO) has been identified to reduce time to treatment.

Dr Peter Chang, radiologist and co-founder of Avicenna.AI, said, “AI-enabled CT stroke triage, specifically with LVO detection, is the first deep learning tool to receive the CMS NTAP designation and is eligible for up to $1040 of reimbursement. CMS only grants NTAP designation to promote the adoption of new technology that provides substantial clinical improvement over standard of care. This will help accelerate the innovation and adoption of deep learning technology by aligning the incentives of both software developers and clinical providers.”

In addition to LVO detection, Avicenna’s FDA-approved CINA Head triage AI solution for neurovascular emergencies also detects intracranial hemorrhages (ICHs). Using a combination of deep learning and machine learning technologies, CINA Head automatically detects and prioritizes acute ICH and LVO cases from CT-scan imaging within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.

Avicenna.ai: NTAP information for customers

Avicenna.AI believes that there is a strong argument that the CINA Head triage solution is substantially similar to the applicant technology and that the same ICD-10-PCS code may be used to describe the use of CINA Head.

Sur le marché de la radiologie, Avicenna.Ai se place en challenger

CT Scan on old man

Sur un marché de plus en plus concurrentiel, Avicenna.AI a choisi de prendre son temps. Ce marché, c’est celui de la radiologie intelligente. Celle qui permet de guider le regard du médecin, de l’aider à détecter des pathologies qui lui auraient échappé à l’œil nu. “Le marché est occupé par des acteurs trop gros pour développer des outils comme le nôtre“, observe Olivier Fuseri, chargé d’affaires de l’entreprise. “Il y a aussi de plus en plus de startups qui organisent d’importantes levées de fonds”.  Face à ces acteurs, Avicenna.Ai a choisi de se placer en challenger. “Nous sommes restés cachés le plus longtemps possible”, le temps de perfectionner sa solution et d’atteindre des performances élevées. Ainsi, alors que la plupart des solutions d’imagerie intelligente indiquent au radiologue le moindre élément anormal – “ce qui lui fait perdre du temps” – le logiciel développé par Avicenna.Ai ne veut l’alerter qu’en cas d’urgence, “avec très peu de faux positifs“.

Car l’idée est bien d‘offrir à un gain de temps à des radiologues souvent en sous-effectifs, mais aussi d’améliorer la prise en charge du patient.

Pour l’heure, l’entreprise a développé trois produits capables de détecter, à partir des scanners du malade, des hémorragies intracérébrales et l’occlusion de gros vaisseaux. Des pathologies pour lesquelles chaque seconde compte. “Chaque seconde, des neurones sont perdus et ne seront jamais régénérés“. D’où l’intérêt d’une prise en charge rapide. “Cela permettra un temps de récupération drastiquement réduit avant de reprendre une vie normale”. Et qui dit meilleure récupération dit moins de coûts pour la collectivité et le système de santé. “C’est moins d’interruptions de travail, moins de complications à soigner…”

En attente d’une certification de la FDA américaine

Après le temps du développement, place à celui du marquage, plus chronophage. Deux produits ont déjà obtenu la certification européenne, ils attendent son équivalent américain, le marquage par la Food and drug administration (ou FDA). “Les États-Unis sont notre principale cible. Lorsque je discute avec de grosses entreprises internationales, elles m’expliquent qu’elles n’investissent pas dans des entreprises françaises qui ne sont pas capables de travailler pour la FDA”. Un Graal pour lequel il faudra patienter encore quelques mois avant la commercialisation prévue au second semestre de cette année.

Et le marché est immense. “Tous les centres, y compris les plus petits, ont des scanners” et sont donc des clients potentiels. Mais pour s’adresser à eux, l’entreprise fait le choix de passer par des distributeurs. “Notre but est de travailler au travers de partenaires formés qui connaissent bien les produits“. Il pourra s’agir de marketplaces ou bien de fournisseurs d’outils en radiologie. “Ceux-ci proposent avant tout du matériel et ne font pas de traitement d’images. Leurs clients leur demandent à ce que cela soit ajouté à leurs outils”. Avicenna.Ai vise aussi les fabricants d’IRM et de scanners qui pourraient eux aussi intégrer le logiciel à leurs produits.

Grâce à ces partenaires, l’entreprise espère voir ses produits présents dans dix à vingt centres de santé d’ici la fin d’année. “Ce sera une année d’incubation pour voir comment le marché se présente“. A terme, l’ambition est de devenir “un des leaders sur l’imagerie d’urgence mais aussi sur d’autres sujets”. L’oncologie pourrait être l’un d’eux. “Cela dépendra des opportunités de recherche qui se présenteront“.

Lisez l’article de presse en intégralité.